Selective induction of CTL helper rather than killer activity by natural epitope variants promotes dendritic cell-mediated HIV-1 dissemination

Journal of Immunology

Volumn 191, Issue 5, 2013, Pages 2570-2580

  Mailliard, Robbie B ^a   Smith, Kellie N ^a   Fecek, Ronald J ^a   Rappocciolo, Giovanna ^a   Nascimento, Eduardo J M ^a   Marques, Ernesto T ^a   Watkins, Simon C ^b   Mullins, James I ^c   Rinaldo, Charles R ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN EXPRESSION; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEEDBACK SYSTEM; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; KILLER CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS PATHOGENESIS; VIRUS TRANSMISSION;

COCULTURE TECHNIQUES; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; MICROSCOPY, ELECTRON, SCANNING; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84883404887     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300373     Document Type: Article

References (59)

1. Musey, L., J. Hughes, T. Schacker, T. Shea, L. Corey, and M. J. McElrath. 1997. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N. Engl. J. Med. 337: 1267-1274.
2. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68: 4650-4655.
3. Deeks, S. G. 2011. HIV infection, inflammation, immunosenescence, and aging. Annu. Rev. Med. 62: 141-155.
4. Goulder, P. J., and D. I. Watkins. 2004. HIV and SIV CTL escape: implications for vaccine design. Nat. Rev. Immunol. 4: 630-640.
5. Liu, Y., J. McNevin, H. Zhao, D. M. Tebit, R. M. Troyer, M. McSweyn, A. K. Ghosh, D. Shriner, E. J. Arts, M. J. McElrath, and J. I. Mullins. 2007. Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape. J. Virol. 81: 12179-12188.
6. Klenerman, P., Y. Wu, and R. Phillips. 2002. HIV: current opinion in escapology. Curr. Opin. Microbiol. 5: 408-413.
7. Cale, E. M., P. Hraber, E. E. Giorgi, W. Fischer, T. Bhattacharya, T. Leitner, W. W. Yeh, C. Gleasner, L. D. Green, C. S. Han, et al. 2011. Epitope-specific CD8+ T lymphocytes cross-recognize mutant simian immunodeficiency virus (SIV) sequences but fail to contain very early evolution and eventual fixation of epitope escape mutations during SIV infection. J. Virol. 85: 3746-3757.
8. Draenert, R., C. L. Verrill, Y. Tang, T. M. Allen, A. G. Wurcel, M. Boczanowski, A. Lechner, A. Y. Kim, T. Suscovich, N. V. Brown, et al. 2004. Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection. J. Virol. 78: 630-641.
9. Iversen, A. K., G. Stewart-Jones, G. H. Learn, N. Christie, C. Sylvester-Hviid, A. E. Armitage, R. Kaul, T. Beattie, J. K. Lee, Y. Li, et al. 2006. Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope. Nat. Immunol. 7: 179-189.
10. Hay, C. M., D. J. Ruhl, N. O. Basgoz, C. C. Wilson, J. M. Billingsley, M. P. DePasquale, R. T. D'Aquila, S. M. Wolinsky, J. M. Crawford, D. C. Montefiori, and B. D. Walker. 1999. Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection. J. Virol. 73: 5509-5519.
11. Christie, N. M., D. O. Willer, M. A. Lobritz, J. K. Chan, E. J. Arts, M. A. Ostrowski, A. Cochrane, M. A. Luscher, and K. S. MacDonald. 2009. Viral fitness implications of variation within an immunodominant CD8+ T-cell epitope of HIV-1. Virology 388: 137-146.
12. Detels, R., L. Jacobson, J. Margolick, O. Martinez-Maza, A. Muñoz, J. Phair, C. Rinaldo, and S. Wolinsky. 2012. The multicenter AIDS Cohort Study, 1983 to.... Public Health 126: 196-198.
13. Shankarappa, R., J. B. Margolick, S. J. Gange, A. G. Rodrigo, D. Upchurch, H. Farzadegan, P. Gupta, C. R. Rinaldo, G. H. Learn, X. He, et al. 1999. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J. Virol. 73: 10489-10502.
14. Pascolo, S., N. Bervas, J. M. Ure, A. G. Smith, F. A. Lemonnier, and B. Pérarnau. 1997. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J. Exp. Med. 185: 2043-2051.
15. Buchli, R., R. S. VanGundy, H. D. Hickman-Miller, C. F. Giberson, W. Bardet, and W. H. Hildebrand. 2005. Development and validation of a fluorescence polarization-based competitive peptide-binding assay for HLA-A*0201 - a new tool for epitope discovery. Biochemistry 44: 12491-12507.
16. Mailliard, R. B., A. Wankowicz-Kalinska, Q. Cai, A. Wesa, C. M. Hilkens, M. L. Kapsenberg, J. M. Kirkwood, W. J. Storkus, and P. Kalinski. 2004. alphatype-1 polarized dendritic cells: a novel immunization tool with optimized CTLinducing activity. Cancer Res. 64: 5934-5937.
17. Keating, S. M., P. Bejon, T. Berthoud, J. M. Vuola, S. Todryk, D. P. Webster, S. J. Dunachie, V. S. Moorthy, S. J. McConkey, S. C. Gilbert, and A. V. Hill. 2005. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J. Immunol. 175: 5675-5680.
18. Balachandran, R., P. Thampatty, A. Enrico, C. Rinaldo, and P. Gupta. 1991. Human immunodeficiency virus isolates from asymptomatic homosexual men and from AIDS patients have distinct biologic and genetic properties. Virology 180: 229-238.
19. Rappocciolo, G., P. Piazza, C. L. Fuller, T. A. Reinhart, S. C. Watkins, D. T. Rowe, M. Jais, P. Gupta, and C. R. Rinaldo. 2006. DC-SIGN on B lymphocytes is required for transmission of HIV-1 to T lymphocytes. PLoS Pathog. 2: e70.
20. Seder, R. A., P. A. Darrah, and M. Roederer. 2008. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8: 247-258.
21. Geijtenbeek, T. B., D. S. Kwon, R. Torensma, S. J. van Vliet, G. C. van Duijnhoven, J. Middel, I. L. Cornelissen, H. S. Nottet, V. N. KewalRamani, D. R. Littman, et al. 2000. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100: 587-597.
22. Rinaldo, C. R. 2013. HIV-1 trans infection of CD4+ T cells by professional antigen presenting cells. Scientifica 2013: 30.
23. Hermans, I. F., D. S. Ritchie, J. Yang, J.M. Roberts, and F. Ronchese. 2000. CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J. Immunol. 164: 3095-3101.
24. Watchmaker, P. B., J. A. Urban, E. Berk, Y. Nakamura, R. B. Mailliard, S. C. Watkins, S. M. van Ham, and P. Kalinski. 2008. Memory CD8+ T cells protect dendritic cells from CTL killing. J. Immunol. 180: 3857-3865.
25. Watkins, S. C., and R. D. Salter. 2005. Functional connectivity between immune cells mediated by tunneling nanotubules. Immunity 23: 309-318.
26. Sowinski, S., C. Jolly, O. Berninghausen, M. A. Purbhoo, A. Chauveau, K. Köhler, S. Oddos, P. Eissmann, F. M. Brodsky, C. Hopkins, et al. 2008. Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission. Nat. Cell Biol. 10: 211-219.
27. Eugenin, E. A., P. J. Gaskill, and J. W. Berman. 2009. Tunneling nanotubes (TNT) are induced by HIV-infection of macrophages: a potential mechanism for intercellular HIV trafficking. Cell. Immunol. 254: 142-148.
28. Langenkamp, A., M. Messi, A. Lanzavecchia, and F. Sallusto. 2000. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat. Immunol. 1: 311-316.
29. Kalínski, P., C. M. Hilkens, E. A. Wierenga, and M. L. Kapsenberg. 1999. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol. Today 20: 561-567.
30. McDonald, D., L. Wu, S. M. Bohks, V. N. KewalRamani, D. Unutmaz, and T. J. Hope. 2003. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 300: 1295-1297.
31. Betts, M. R., D. A. Price, J. M. Brenchley, K. Loré, F. J. Guenaga, A. Smed-Sorensen, D. R. Ambrozak, S. A. Migueles, M. Connors, M. Roederer, et al. 2004. The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration. J. Immunol. 172: 6407-6417.
32. Wu, L., and V. N. KewalRamani. 2006. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat. Rev. Immunol. 6: 859-868.
33. Mailliard, R. B., S. Egawa, Q. Cai, A. Kalinska, S. N. Bykovskaya, M. T. Lotze, M. L. Kapsenberg, W. J. Storkus, and P. Kalinski. 2002. Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. J. Exp. Med. 195: 473-483.
34. Dragic, T., V. Litwin, G. P. Allaway, S. R. Martin, Y. Huang, K. A. Nagashima, C. Cayanan, P. J. Maddon, R. A. Koup, J. P. Moore, and W. A. Paxton. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381: 667-673.
35. Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R. E. Sutton, C. M. Hill, et al. 1996. Identification of a major coreceptor for primary isolates of HIV-1. Nature 381: 661-666.
36. Loré, K., A. Smed-Sörensen, J. Vasudevan, J. R. Mascola, and R. A. Koup. 2005. Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells. J. Exp. Med. 201: 2023-2033.
37. Sanders, R. W., E. C. de Jong, C. E. Baldwin, J. H. Schuitemaker, M. L. Kapsenberg, and B. Berkhout. 2002. Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. J. Virol. 76: 7812-7821.
38. Ruedl, C., M. Kopf, and M. F. Bachmann. 1999. CD8(+) T cells mediate CD40-independent maturation of dendritic cells in vivo. J. Exp. Med. 189: 1875-1884.
39. Gurunathan, S., L. Stobie, C. Prussin, D. L. Sacks, N. Glaichenhaus, A. Iwasaki, D. J. Fowell, R. M. Locksley, J. T. Chang, C. Y. Wu, and R. A. Seder. 2000. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells. J. Immunol. 165: 915-924.
40. Thomas, M. J., A. Noble, E. Sawicka, P. W. Askenase, and D. M. Kemeny. 2002. CD8 T cells inhibit IgE via dendritic cell IL-12 induction that promotes Th1 T cell counter-regulation. J. Immunol. 168: 216-223.
41. Welsh, R. M., J. W. Che, M. A. Brehm, and L. K. Selin. 2010. Heterologous immunity between viruses. Immunol. Rev. 235: 244-266.
42. Nakamura, Y., P.Watchmaker, J. Urban, B. Sheridan, A. Giermasz, F. Nishimura, K. Sasaki, R. Cumberland, R. Muthuswamy, R. B. Mailliard, et al. 2007. Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Res. 67: 10012-10018.
43. Kalinski, P., and M. Moser. 2005. Consensual immunity: success-driven development of T-helper-1 and T-helper-2 responses. Nat. Rev. Immunol. 5: 251-260.
44. Valentine, L. E., S. M. Piaskowski, E. G. Rakasz, N. L. Henry, N. A. Wilson, and D. I. Watkins. 2008. Recognition of escape variants in ELISPOT does not always predict CD8+ T-cell recognition of simian immunodeficiency virus-infected cells expressing the same variant sequences. J. Virol. 82: 575-581.
45. Loffredo, J. T., B. J. Burwitz, E. G. Rakasz, S. P. Spencer, J. J. Stephany, J. P. Vela, S. R. Martin, J. Reed, S. M. Piaskowski, J. Furlott, et al. 2007. The antiviral efficacy of simian immunodeficiency virus-specific CD8+ T cells is unrelated to epitope specificity and is abrogated by viral escape. J. Virol. 81: 2624-2634.
46. Maile, R., C. A. Siler, S. E. Kerry, K. E. Midkiff, E. J. Collins, and J. A. Frelinger. 2005. Peripheral "CD8 tuning" dynamically modulates the size and responsiveness of an antigen-specific T cell pool in vivo. J. Immunol. 174: 619-627.
47. Xiao, Z., M. F. Mescher, and S. C. Jameson. 2007. Detuning CD8 T cells: downregulation of CD8 expression, tetramer binding, and response during CTL activation. J. Exp. Med. 204: 2667-2677.
48. Wolint, P., M. R. Betts, R. A. Koup, and A. Oxenius. 2004. Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8+ T cells. J. Exp. Med. 199: 925-936.
49. Daniels, M. A., and S. C. Jameson. 2000. Critical role for CD8 in T cell receptor binding and activation by peptide/major histocompatibility complex multimers. J. Exp. Med. 191: 335-346.
50. Yachi, P. P., J. Ampudia, T. Zal, and N. R. Gascoigne. 2006. Altered peptide ligands induce delayed CD8-T cell receptor interaction - a role for CD8 in distinguishing antigen quality. Immunity 25: 203-211.
51. Wooldridge, L., B. Laugel, J. Ekeruche, M. Clement, H. A. van den Berg, D. A. Price, and A. K. Sewell. 2010. CD8 controls T cell cross-reactivity. J. Immunol. 185: 4625-4632.
52. Brockman, M. A., Z. L. Brumme, C. J. Brumme, T. Miura, J. Sela, P. C. Rosato, C. M. Kadie, J. M. Carlson, T. J. Markle, H. Streeck, et al. 2010. Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J. Virol. 84: 11937-11949.
53. Goulder, P. J., M. A. Altfeld, E. S. Rosenberg, T. Nguyen, Y. Tang, R. L. Eldridge, M. M. Addo, S. He, J. S. Mukherjee, M. N. Phillips, et al. 2001. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J. Exp. Med. 193: 181-194.
54. Brander, C., K. E. Hartman, A. K. Trocha, N. G. Jones, R. P. Johnson, B. Korber, P. Wentworth, S. P. Buchbinder, S. Wolinsky, B. D. Walker, and S. A. Kalams. 1998. Lack of strong immune selection pressure by the immunodominant, HLAA* 0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection. J. Clin. Invest. 101: 2559-2566.
55. Brander, C., P. J. Goulder, K. Luzuriaga, O. O. Yang, K. E. Hartman, N. G. Jones, B. D. Walker, and S. A. Kalams. 1999. Persistent HIV-1-specific CTL clonal expansion despite high viral burden post in utero HIV-1 infection. J. Immunol. 162: 4796-4800.
56. Klenerman, P., and R. M. Zinkernagel. 1998. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 394: 482-485.
57. Duerr, A., Y. Huang, S. Buchbinder, R. W. Coombs, J. Sanchez, C. del Rio, M. Casapia, S. Santiago, P. Gilbert, L. Corey, and M. N. Robertson; Step/HVTN 504 Study Team. 2012. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J. Infect. Dis. 206: 258-266.
58. Rolland, M., S. Tovanabutra, A. C. deCamp, N. Frahm, P. B. Gilbert, E. Sanders-Buell, L. Heath, C. A. Magaret, M. Bose, A. Bradfield, et al. 2011. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat. Med. 17: 366-371.
59. Rothman, A. L. 2011. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat. Rev. Immunol. 11: 532-543.